Enclosed is the investor presentation Q1FY27

1th August,2026 BSE Limited National Stock Exchange of India Limited Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Investor Presentation for Quarter ended 30th June, 2026 Dear Sir/Madam In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for Quarter ended 30th June, 2026 is enclosed. The aforesaid presentation is also available on the Company’s website. You are requested to take the same on record. Thanking You. For Clean Science and Technology Limited Ruchita Vij Company Secretary and Compliance Officer Encl: As above Clean Science and Technology Ltd. Investor Presentation Q1 FY 2027 I August 2026 SAFE HARBOUR This investor presentation has been prepared by Clean Science and Technology Limited (“CSTL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward-looking statements”, including those relating to the general business plans and strategy of Clean Science and Technology , its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. Clean Science and Technology Limited may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. Q1 FY 2027 Business Update Q1 FY2027 UPDATE - Standalone Company reported steady performance during the quarter, despite global headwinds Revenue in INR Crore 228 232 245 220 212 185 197 207 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 42.1% 44.8% 43.8% 46.4% 44.3% 45.6% 42.7% 40.3% 36.6% 35.7% 37.3% 34.7% 36.1% 34.6% 32.5% 33.3% 9.6% 8.4% 7.9% 9.2% 10.2% 9.8% 11.7% 10.8% Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Note: RM -raw material; P&F –power & fuel P&F costs % RM costs % EBITDA % ➢ Incurred total capex of ~ Rs. 100 crores during Q1 FY2027 towards investment in Clean Fino Chem Ltd. (CFCL),wholly owned subsidiary of CSTL CAPEX & ➢ Establishing a wholly owned European subsidiary to expand global footprint, strengthen customer proximity, deepen market engagement and accelerate global growth BUSINESS UPDATE ➢ Performance Chemical 2, expected to commercialisedby Q3FY 27. Q1 FY2027 P&L OVERVIEW Highest-Ever Consolidated Sales in Company’s History P&L (INRCrore) STANDALONE CONSOLIDATED Particular Q1 FY2027 Q4 FY2026 Q-o-Q (%) Q1 FY2026 Y-o-Y (%) Q1 FY2027 Q4 FY2026 Q-o-Q (%) Q1 FY2026 Y-o-Y (%) Saleof products 203 193 5% 217 (6%) 264 246 7% 240 10% Other operating income 4 4 3 4 3 3 Total Revenue 207 197 5% 220 (6)% 268 249 8% 243 11% Raw materialexpenses 70 64 9% 70 - 105 91 15% 84 25% Rawmaterial % 34.6% 33.3% 32.5% 39.7% 37.0% 35.0% Otheroperating expenses 50 45 12% 49 2% 67 62 7% 59 13% EBITDA 87 88 (1%) 101 (14%) 96 96 1% 100 (3%) EBITDA % 42.7% 45.6% 46.4% 36.5% 38.9% 41.6% Depreciation expenses 11 11 11 21 21 19 Finance costs 0 0 0 0 0 0 Other Income 21 0 13 22 3 13 Profit before tax (PBT) 97 77 26% 102 (5%) 98 78 26% 94 3% PBT % 48.0% 40.0% 47.3% 36.9% 31.6% 39.3% Profit after tax (PAT) 73 58 26% 77 (4%) 73 58 26% 70 5% PAT % 36.0% 30.1% 35.3% 27.8% 23.7% 29.1% REVENUE PROFILE –Q1 FY 2027 - Consolidated Performance segment share increased led by higher sales of HALS series REVENUE MIX BY SEGMENT Q1 FY’27 Q1 FY’26 Performance chemicals Pharma & Agro FMCG chemicals Intermediates ➢ Strategic collaboration with a Swiss technology partner enabling access to differentiated chemistry capabilities. Synergizing advanced technologies with our proven HALS Business manufacturing excellence to accelerate advanced HALS development and strengthen technology leadership Update ➢ Successfullyde-risked product concentration, with the top four legacy products' contribution declining from ~85% in Q4 FY23 to ~60% this quarter; HALSnow accounts for 22% of sales Corporate presentation CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE A brief Introduction about the Company ➢One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest manufacturers of certain specialty chemicals developed in-house. ➢Among the few global organizations focused on developing ingenious technologies with unique, innovative, sustainable, and cost- effective catalytic manufacturing processes 500+ 1,600+ Global Strong team 16+ Zero Debt Accreditation & Company and domestic customers across ( women staff) Certifications countries Sustainability 4 and manufacturing units 65+ 61% Scientists over ESG consolidated revenues State-of-art Pilot facility deeply ingrained in our 4 from exports R&D facilities philosophy Fully equipped Application lab COMPANY EVOLUTION Continuous R&D and Innovation has led to new product launches on a consistent basis YEAR 2009 2011 2014 2018 2020 2021 2022 2023 2024 2025 2026 REVENUES 1 19 120 241 419 512 685 936 789 967 957 (INR Crore) ➢ Commercialized largest plant for 2025 2026 Genesis: HALS from India 2023 ➢ Technocrat Promoters 2022 collaborated to develop ➢ Commercialized TBHQ 2024 novel, clean and sustainable ➢ Commercialized ➢ launched chemical processes ➢ Expanded HALS 770 & ➢ Commercializ HQ & ➢ Aligned to the philosophy, 2020 2021 capacity of 701 ed BHT Catechol Company was named as ➢ Recorded MEHQ, Guaiacol ➢ Commercialized unique vapor Clean Science and highest and BHA by 50% phase route for Anisole Technology volume ➢ Backward integration ➢ Commercialized across for flagship products unique technology products process for DCC ➢ Commercialized unique catalytic process for 4-MAP 2014 2018 2009 ➢ Commercialized unique 2011 catalytic forward ➢ Commercialized unique integration process for catalytic process for BHA MEHQ and Guaiacol DIVERSIFIED PRODUCT PROFILE SERVING CRITICAL END-USER INDUSTRIES Largest capacity in the world for our flagship products PERFORMANCE PHARMA AND AGRO FMCG CHEMICALS INTERMEDIATES CHEMICALS MEHQ(Monomethyl Ether of Hydroquinone) Guaiacol 4-MAP (4-Methoxy Acetophenone) ➢ Used as polymerization inhibitor in acrylic acids, acrylic esters, super ➢ Pre-cursor to manufacture APIs for cough absorbent polymers (diapers and sanitary pads) syrup (pharmaindustry) ➢ Used in UV blocker in sunscreens ➢ Pre-cursor for agrochemical industry ➢ Key raw material to produce Vanillin (cosmetics industry) 1 Globally 2 Globally 1 in India BHA (Butylated Hydroxy Anisole) 1 Globally ➢ Used as anti-oxidant in food and feed industry DCC (Dicyclohexyl Carbodiimide) 1 Globally ➢ Used as reagent in anti-retroviral AP (Ascorbyl Palmitate) ➢ Used in infant food formulations, breakfast cereals and cosmetics 2 Globally 1 in India Anisole 1 Globally Veratrole ➢ Precursor to perfumes, insect TBHQ (Tertiary Butyl Hydroquinone [Showing first 8,000 characters — download PDF for full document]